Breast Cancer : Targets and Therapy最新文献

{"title":"Effectiveness of a Care Plan Based on the Multi-Theory Model in Reducing Fear of Disease Progression and Improving Quality of Life in Breast Cancer Patients: A Randomized Controlled Trial.","authors":"Jiajia Zhang, Jiaru Zhuang, Xian Chen, Tianyu Chu, Qian Zhang, Linlin Ma, Hui Zhou, Yibo Wu, Ling Chen","doi":"10.2147/BCTT.S534595","DOIUrl":"10.2147/BCTT.S534595","url":null,"abstract":"<p><strong>Purpose: </strong>Fear of progression has become a prominent mental health problem. Our research aimed to evaluate the effectiveness of a care plan based on the Multi-Theory Model of health behavior change in reducing fear of progression in breast cancer patients undergoing adjuvant chemotherapy.</p><p><strong>Patients and methods: </strong>This randomized controlled trial enrolled 108 eligible participants receiving adjuvant chemotherapy at Jiangnan University Affiliated Hospital between May and December 2024. Routine care was administered to the control group, while the intervention group received the multi-theoretical model-based nursing intervention program integrated with general nursing. The evaluation time points included pre-intervention, immediately post-intervention (after 6 weeks), and 1-month post-intervention. Data were analyzed using Fisher's exact test or chi-square test, Mann-Whitney <i>U</i>-test, independent samples <i>t</i>-test, generalized estimating equations, or repeated measures ANOVA.</p><p><strong>Results: </strong>At various post-intervention assessments, the Multi-Theory Model group demonstrated significantly lower fear of progression scores along with higher self-management efficacy and quality of life scores, compared to the control group (<i>p</i> < 0.05). There were time, between-group, and interaction effects for the differences in the total scores of quality of life, self-management efficacy, and fear of progression between the two groups of participants (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>A nursing program grounded in the multi-theoretical model reduced the level of fear of progression, and improved quality of life and self-management efficacy in patients with breast cancer undergoing postoperative chemotherapy. These findings can provide a reference for psychological interventions in clinical settings for breast cancer patients.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"653-667"},"PeriodicalIF":3.4,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Prognosis and Nomograms for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Patients Treated with Palbociclib and Endocrine Therapy.","authors":"Shubin Song, Luhao Sun, Xiaoyu Liu, Liang Zhang, Chao Li, Zhaoyun Liu, Fengzhen Liu, Zhiyong Yu","doi":"10.2147/BCTT.S523199","DOIUrl":"10.2147/BCTT.S523199","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to analyze factors affecting the prognosis of patients with hormone receptor-positive (HR+) and human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) treated with palbociclib and endocrine therapy (ET).</p><p><strong>Methods: </strong>Patients with HR+/HER2- MBC who were treated with palbociclib plus ET between January 2019 and December 2020 at Shandong Cancer Hospital were recruited. Clinicopathological data, treatment outcomes, and survival were from electronic medical system and telephone follow-up.</p><p><strong>Results: </strong>A total of 90 eligible patients were recruited in this study; 55 (61.11%) patients preferred chemotherapy as first treatment, and 35 (38.89%) preferred ET as first treatment. The percentages for 1st, 2nd line, and ≥3 lines applying palbociclib were 17.78%, 16.66%, and 65.56%, respectively. In the univariate analysis, multiple factors influenced the primary overall survival (pOS, from initial diagnosis of BC to death), progression-free survival (PFS), and mOS (from diagnosis of metastasis to death). Meanwhile in the multivariate analysis, pPR (progesterone receptor of primary tumor) and prior ET response were independent risk factors for pOS, PFS, and mOS. Lower pPR and prior ET resistance predicted poorer pOS, PFS, and mOS in HR+/HER2- MBC patients. Number of lines of palbociclib application was an independent risk factor for pOS and mOS and presented higher points both in the pOS and mOS nomograms, meaning that palbociclib had a more significant impact on pOS and mOS compared to other factors. The nomograms showed excellent discrimination and prediction accuracy with area under curves (AUC) of 0.974 for pOS, 0.627 for PFS, and 0.881 for mOS, respectively.</p><p><strong>Conclusion: </strong>This real-world single-center study of patients with HR+/HER2- MBC showed that early application of palbociclib combined with ET may bring better PFS, but not pOS and mOS. pPR and prior ET response were independent risk factors affecting prognosis.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"669-681"},"PeriodicalIF":3.4,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"N2 Neutrophils and Tumor Progression in Breast Cancer: Molecular Pathways and Implications.","authors":"Emmanuel Ifeanyi Obeagu","doi":"10.2147/BCTT.S542787","DOIUrl":"10.2147/BCTT.S542787","url":null,"abstract":"<p><p>Neutrophils, traditionally viewed as first-line defenders in innate immunity, are increasingly recognized for their dualistic roles in cancer. In breast cancer, a distinct subset known as N2 neutrophils exhibits pro-tumorigenic activity, facilitating angiogenesis, immune suppression, and metastasis. This narrative review synthesizes current evidence on the molecular mechanisms underlying N2 polarization-focusing on key pathways such as TGF-β, STAT3/6, and hypoxia-mediated signaling-and their implications in breast cancer progression. We further explore how N2 neutrophils interact with other immune cells within the tumor microenvironment to promote an immunosuppressive milieu. A unique contribution of this review lies in its integration of emerging single-cell and flow cytometry data to underscore neutrophil plasticity and subtype-specific differences in neutrophil activity across breast cancer variants. Therapeutic strategies targeting N2 neutrophils are critically examined, including small-molecule inhibitors, cytokine blockade, and neutrophil-targeted nanomedicine. However, major challenges persist-most notably the difficulty in selectively depleting or reprogramming N2 neutrophils without compromising essential antimicrobial functions. Additionally, the lack of validated N2-specific markers in clinical samples limits translational progress. Addressing these gaps is crucial for the development of safe, effective immunomodulatory therapies in breast cancer.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"639-651"},"PeriodicalIF":3.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144727939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral TNF-α and CD8⁺/CD28⁺ T Lymphocytes as Alternatives for PD-L1 Prediction in Breast Cancer Tumor Microenvironment: Stratified by Neoadjuvant Therapy.","authors":"Jiangping Wu, Xin Ou, Keyu Yuan, Feng Shi, Quan Zhou, Suzhen Lyu, Yanping Li, Yanjie Zhao, Yu Cao, Jianping Sun, Qingkun Song","doi":"10.2147/BCTT.S532688","DOIUrl":"10.2147/BCTT.S532688","url":null,"abstract":"<p><strong>Background: </strong>Programmed death-ligand 1 (PD-L1) is an immunotherapy target; however, its detection is based on biopsy tissues, and repeated biopsies present clinical challenges. This study aimed to explore peripheral blood-based alternatives to PD-L1 tissue detection in breast cancer (BC), particularly stratification by neoadjuvant therapy (NAT).</p><p><strong>Methods: </strong>A total of 134 cases were recruited, the peripheral lymphocyte subtypes and cytokines were detected by flow cytometry and PD-L1 expression in tumor microenvironment (TME) was detected by immunohistochemistry and assessed by two qualified pathologists.</p><p><strong>Results: </strong>The patients with positive PD-L1 expression had peripheral CD8⁺/CD28⁺ T lymphocytes 20% higher than those with negative expression (<i>p</i> = 0.008) with the area under the receiver operating characteristic curve (AUC) being 0.64 (<i>p</i> = 0.002). Among patients with negative NAT, positive PD-L1 expression was associated with peripheral CD8⁺/CD28⁺ T lymphocytes that increased by 54% (<i>p</i> = 0.003), and the AUC being 0.68 (<i>p</i> = 0.003). In patients receiving NAT, positive PD-L1 expression was associated with peripheral TNF-α (<i>p</i> = 0.010), which increased from 0.45pg/mL to 0.64pg/mL in the PD-L1 positive group, and the AUC was 0.79 (<i>p</i> = 0.012). Among patients without NAT experience, a 1% increase in peripheral CD8⁺/CD28⁺ T lymphocytes was associated with a 21% higher probability of positive PD-L1 expression (OR = 1.21, 95% CI: 1.06-1.37) and among patients with NAT, the OR of peripheral TNF-α (>0.5pg/mL) increased to 24.5 for positive TME PD-L1 expression (<i>p</i> = 0.008).</p><p><strong>Conclusion: </strong>Peripheral CD8⁺/CD28⁺ T cell percentages and TNF-α levels served as non-invasive biomarkers for TME PD-L1 expression in BC patients with and without NAT, respectively. These biomarkers warranted further validation in clinical implementation to guide precision immunotherapy.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"627-637"},"PeriodicalIF":3.4,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Machine-Learning Model for the Prediction of Triple-Negative Breast Cancer Based on Multiparameter MRI.","authors":"Yuxin Cai, Yanbo Li, Wenqi Wang, Yaqiu Zhou, Jingbo Wang, Lina Zhang, Hong Lu","doi":"10.2147/BCTT.S513779","DOIUrl":"10.2147/BCTT.S513779","url":null,"abstract":"<p><strong>Objective: </strong>To explore the difference between triple-negative breast cancer (TNBC) and non-triple-negative breast cancer (non-TNBC) based on multi-parametric MRI imaging features and construct a prediction model to identify TNBC.</p><p><strong>Methods: </strong>A retrospective study enrolled 1353 women with 1376 malignant lesions who had no additional therapy before surgery between January 2019 and December 2020 in a single center. The images were accessed according to BI-RADS-MR^® (fifth ed.) atlas. The lesions were classified as TNBC group and non-TNBC and then randomly divided into a primary cohort (n = 963) and a validation cohort (n = 413) at a ratio of 7:3. In the primary cohort, univariate analysis, logistic regression analysis and Boruta algorithm were used to determine the independent predictors for TNBC and non-TNBC. The machine learning classifier XGboost was developed based on the features to predict TNBC. The area under the receiver operating characteristic (ROC) curve (AUC) was applied to evaluate the model prediction ability. The diagnostic performances of the model were evaluated in the validation cohort.</p><p><strong>Results: </strong>Necrosis, edema, the maximum diameter of lesions, enhancement ratio in each phase, time to peak, gland enhancement ratio, wash-in slope and the number and diameter of the vessels were independent predictors predicting TNBC. The AUCs of the model were 0.795 (95% CI: 0.758-0.832) and 0.705 (95% CI: 0.640-0.770) in the primary cohort and validation cohort, respectively.</p><p><strong>Conclusion: </strong>The model based on multiparameter MRI has good predictive ability and can be used to predict the probability of TNBC.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"611-625"},"PeriodicalIF":3.3,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Mechanism of Lianqiao Jinbei Decoction Inhibiting HER2-Positive Breast Cancer Based on Network Pharmacology and Experimental Verification.","authors":"Dehui Li, Xukuo Liu, Huanfang Fan, Jingfei Dong, Liying Wei, Na Guo, Zhengrong Wang, Zhihua Du, Jiao Liu, Xiaohui Zhao, Xiaotong Tian, Changhui Han, Xujiong Yao","doi":"10.2147/BCTT.S522528","DOIUrl":"10.2147/BCTT.S522528","url":null,"abstract":"<p><strong>Purpose: </strong>Through network pharmacological prediction and in vitro experimental verification, the mechanism of action of Lianqiao Jinbei Decoction (LJD) in inhibiting HER2-positive breast cancer cells was clarified, providing experimental evidence for its treatment of HER2-positive breast cancer.</p><p><strong>Methods: </strong>Network pharmacology method was used to construct the potential target network of LJD in the treatment of HER2+ breast cancer. After cell culture in vitro, the proliferation of HER2+ SK-BR3 breast cancer cells was investigated using CCK-8 technique. The apoptotic potential of SK-BR3 cells was detected by flow cytometry, and the migration of SK-BR3 cells was detected by cell scratch assay. The expression of HER2 protein in SK-BR3 breast cancer cells was detected by ELISA.</p><p><strong>Results: </strong>HER2 was identified as the central gene and quercetin, β-sitosterol, and luteolin were the primary active ingredients using network pharmacology analysis. Serum-containing LJD medication can stop SK-BR3 cells from proliferating (<i>P</i><0.05). Serum-containing LJD drugs at high, medium, and low concentrations may induce SK-BR3 cell death (<i>P</i><0.05). LJD serum at high, medium, and low concentrations reduced the migration of SK-BR3 cells (<i>P</i><0.05). The expression of HER2 protein was decreased by LJD high, medium, and low concentration drug-containing serum (<i>P</i><0.05).</p><p><strong>Conclusion: </strong>Regarding treating HER2-positive breast cancer, LJD has a multi-component, multi-target, and multi-pathway mode of action. The primary target of LJD's activity is the HER2 protein. Serum-containing LJD medication can prevent SK-BR3 cells from proliferating and migrating while encouraging their apoptosis. This effect may be attained by preventing HER2 protein expression.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"583-598"},"PeriodicalIF":3.3,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12273717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous Implant and Dermal Flap Technique for Breast Reconstruction After Skin-Sparing Total Mastectomy for Breast Carcinoma.","authors":"Özgür Agdoğan, Sibel Gürdal Özkan","doi":"10.2147/BCTT.S524455","DOIUrl":"10.2147/BCTT.S524455","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the simultaneous implant and dermal flap technique for breast reconstruction following skin-sparing total mastectomy in breast carcinoma patients, assessing both oncological and aesthetic outcomes.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 28 patients who underwent skin-sparing total mastectomy with preservation of the nipple-areola complex, followed by immediate breast reconstruction using implants and dermal flaps. Data on patient demographics, surgical outcomes, complications, and patient satisfaction were collected and analyzed.</p><p><strong>Results: </strong>The study included 28 patients with an average age of 54.3 years. The implant sizes used ranged from 200 to 325 cc. Among these patients, 7 were chronic smokers and 8 had chronic diseases. A total of 22 patients underwent bilateral mastectomies, while 6 had unilateral mastectomies. Axillary lymph node dissection was performed in all cases. Preoperative radiotherapy was administered to 3 patients, and postoperative radiotherapy was given to 5 patients. Two patients experienced unilateral complete necrosis of the NAC and skin, while one patient had partial NAC necrosis. No evidence of capsular contracture, tumor recurrence, or metastasis was observed during the follow-up period. Patient satisfaction was high, with 24 out of 28 patients expressing positive outcomes.</p><p><strong>Conclusion: </strong>Simultaneous implant and dermal flap breast reconstruction after skin-sparing total mastectomy offers a viable single-session approach with optimal cosmetic results, minimal morbidity, and high patient satisfaction. This technique is particularly beneficial for patients seeking immediate reconstruction with preserved nipple-areola complex.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"599-610"},"PeriodicalIF":3.3,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity Assessment of Breast Cancer Tumor Microenvironment: Multiparametric Quantitative Analysis with DCE-MRI and Discovery of Radiomics Biomarkers.","authors":"Wenhui Ma, Lu Yang, Yu Zhang, Yuan Gao, Huan Jie, Cong Huang","doi":"10.2147/BCTT.S530834","DOIUrl":"10.2147/BCTT.S530834","url":null,"abstract":"<p><p>The heterogeneity of the tumor microenvironment (TME) in breast cancer significantly influences therapeutic response and prognosis, yet noninvasive evaluation remains a clinical challenge. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), through multiparametric quantitative analysis (eg, K^trans, V_e, K_ep), enables dynamic characterization of tumor vascularization and perfusion heterogeneity. Concurrently, radiomics technology, leveraging high-throughput feature extraction and machine learning modeling, identifies potential biomarkers associated with TME biological properties. This review systematically examines the integration strategies of DCE-MRI multiparametric quantification and radiomics: first, elucidating the capability of DCE-MRI pharmacokinetic models to quantify microvascular heterogeneity, and delineating radiomics feature screening and predictive model construction based on 3D segmentation. Furthermore, it explores the combined application of these techniques in evaluating angiogenesis, resolving immune microenvironment dynamics, and mapping metabolic heterogeneity, with emphasis on clinical translational evidence in molecular subtype discrimination, treatment response prediction, and prognostic assessment. Key limitations persist in technical standardization (eg, 37% variability in Ktrans values across 1.5T/3.0T systems) and biological interpretability, with fewer than 40% of radiomics features linked to known molecular pathways. Future advancements demand multicenter data harmonization, radiogenomics integration, and digital twin technology to optimize personalized therapeutic navigation systems. This work provides methodological insights and technical innovation pathways for noninvasive TME heterogeneity assessment in breast cancer.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"573-581"},"PeriodicalIF":3.3,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Male Breast Cancer: Evaluating the Current Landscape of Diagnosis and Treatment.","authors":"Anna Ter-Zakarian, Alex Agelidis, Mohammed Jaloudi","doi":"10.2147/BCTT.S516124","DOIUrl":"10.2147/BCTT.S516124","url":null,"abstract":"<p><p>Male breast cancer (MBC) is a rare condition, comprising less than 1% of all breast cancer cases. This review examines the epidemiology, risk factors, clinical presentation, diagnostic approaches, and treatment strategies for MBC in both early and advanced stages. Early diagnosis of MBC poses a significant challenge, as men typically present with more advanced disease than women with breast cancer, likely due to limited awareness and delayed medical care. Data guiding treatment strategies remain limited, as most clinical trials have historically excluded male participants. This review provides a comprehensive analysis of recent advances in MBC, critically examines current diagnostic and therapeutic gaps, and outlines emerging research priorities. By emphasizing the limitations of existing evidence and the urgent need for male-specific clinical trials, this manuscript presents a forward-looking perspective aimed at fostering more inclusive research to develop tailored, evidence-based strategies for male patients.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"567-572"},"PeriodicalIF":3.3,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review.","authors":"Zhimin Chen, Pengjun Xie, Qihai Chen, Jie Ouyang","doi":"10.2147/BCTT.S529794","DOIUrl":"10.2147/BCTT.S529794","url":null,"abstract":"<p><p>Combining cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6 inhibitors) with cyclin-dependent proteins can reduce the formation of cyclin D-CDK4/6 complexes, resulting in the inactivation of downstream genes and suppression of cell proliferation. Previous research on the use of CDK4/6 inhibitors in combination with endocrine therapies and anti-HER2 targeting agents across various subtypes and stages of breast cancer has shown promising outcomes in patient prognoses and tolerable drugs toxicities. For the present, the CDK4/6 inhibitors that have been widely used for the treatment of breast cancer are palbociclib, abemaciclib and ribociclib. Dalpiciclib (SHR6390), a novel and selective CDK4/6 inhibitor developed in China, has been approved by the National Medical Products Administration. The researches about dalpiciclib with different anti-tumor drugs are ongoing to explore the efficacy and the best strategies to use dalpiciclib. This review provides an overview of the research progress on dalpiciclib across different breast cancer subtypes with various anti-tumor drugs in different treatment opportunities.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"557-565"},"PeriodicalIF":3.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}